63rd ASH Annual Meeting and Exposition: 802. Chemical Biology and Experimental Therapeutics

Oral and Poster Abstracts
Oral

Fundamental Science, Translational Research, Therapies, Technology and Procedures

C108-C109, Level 1, Building C (Georgia World Congress Center)

Moderator:

and Joanna S. Yi, MD, Texas Children's Hospital

Disclosures:

No relevant conflicts of interest to declare.

2:00 PM

Mapping the High-Risk Multiple Myeloma Cell Surface Proteome Identifies T-Cell Inhibitory Receptors for Immune Targeting

Francesco Di Meo¹^*, Christina Yu¹^*, Annamaria Cesarano¹^*, Aljoufi Arafat²^*, Silvia Marino, PhD¹, G David Roodman, MD, PhD¹, Hal E. Broxmeyer, PhD² and Fabiana Perna, MD, PhD¹

¹Department of Medicine, Indiana University School of Medicine, Indianapolis, IN
²Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN

2:15 PM

266

An In Vivo CRISPR Screening Platform to Identify New Therapeutic Targets in AML

Shan Lin, PhD^1,2, Clement Larrue³^*, Nastassja K. Scheidegger¹^*, Bo Kyung A. Seong¹^*, Neekesh V Dharia, MD, PhD^1,2^*, Caroline Wechsler¹^*, Guillaume Kugener²^*, Amanda L Robinchaud¹^*, Amy Conway¹^*, Biniam Adane¹^*, Scott Younger, PhD^2,4^*, Federica Piccioni, PhD²^*, Lynn Lee⁵^*, Mark Wunderlich, MS⁶^*, Jerome Tamburini³^* and Kimberly Stegmaier, MD^1,2

¹Dana-Farber Cancer Institute, Boston, MA
²Broad Institute of MIT and Harvard, Cambridge, MA
³Translational Research Centre In Onco-Hematology, Faculty of Medicine, University of Geneva, Geneva, Switzerland
⁴Children's Mercy Kansas City, Children's Mercy Research Institute, Kansas City, MO
⁵Division of Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
⁶Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

2:30 PM

267

Pharmacological Reduction of Mitochondrial Iron in AML Triggers a BAX/BAK Dependent Non-Canonical Cell Death Synergistic with Venetoclax

Sylvain Garciaz^1,2,3^*, Sebastian Müller⁴^*, Andrew Guirguis²^*, Fiona C. Brown^5,6^*, Yih-Chih Chan²^*, Mathilde Poplineau^1,7, Kevin Tran²^*, Kah-Lok Chan²^*, Laura MacPherson²^*, Brian Liddicoat²^*, Enid Y. N. Lam²^*, Tatiana Cañeque⁴^*, Marian L. Burr²^*, Veronique Litalien⁶^*, Giovanna Pomilio⁸^*, Estelle Duprez⁹^*, David C.S. Huang, MBBS, PhD¹⁰^*, Sarah-Jane Dawson¹¹^*, Georg Ramm¹²^*, Andrew G. Cox²^*, Kristin K. Brown²^*, Andrew H. Wei, MBBS, PhD¹³, Kate McArthur¹⁴^*, Raphael Rodriguez⁴^* and Mark A. Dawson²

¹Institut Paoli-Calmettes, CRCM, Marseille, France
²Peter MacCallum Cancer Centre, Melbourne, Australia
³Institut Paoli Calmettes, Institut Paoli-Calmettes, Marseille, France
⁴Institut Curie, Paris, France
⁵Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia
⁶Monash University, Australian Centre for Blood Diseases, Melbourne, Australia
⁷CRCM, Marseille, France
⁸Australian Centre for Blood Diseases, Melbourne, Australia
⁹Centre de Recherche en Cancérologie de Marseille, Marseille, France
¹⁰The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
¹¹Peter Maccallum Cancer Centre, Melbourne, Australia
¹²Monash University, Melbourne, Australia
¹³The Alfred Hospital and Monash University, Melbourne, Australia
¹⁴Monash University, Clayton, Australia

2:45 PM

268

Custom High Throughput Drug Sensitivity Assay Reveals Therapeutic Options for Chronic Myeloid Leukemia Patients Resistant to or Intolerant of Tyrosine Kinase Inhibitors

Vivian G. Oehler, MD^1,2, Sylvia Chien, MS³^*, Jin Dai, PhD³^*, Carrie L. Cummings²^*, James Annis⁴^*, Timothy J Martins, PhD⁴^* and Pamela S. Becker, MD, PhD^1,5

¹Department of Medicine, Division of Hematology, University of Washington, Seattle, WA
²Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
³Department of Medicine, University of Washington, Seattle, WA
⁴Institute for Stem Cell and Regenerative Medicine/Department of Medicine, University of Washington, Seattle, WA
⁵Division of Hematology/Oncology, University of California, Irvine, Irvine, CA

3:00 PM

269

MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Madhav R Seshadri, MD¹, Lorena Fontan, PhD¹, Prasanna Sreevatsan, PhD^2,3^*, David Scott, PhD^2,3^*, John Hatcher, PhD^2,3^*, Guangyan Du, PhD^2,3^*, Min Xia, PhD¹, Ilkay Us¹^*, Nathanael Gray, PhD^2,3^* and Ari Melnick, MD¹

¹Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY
²Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA
³Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA

3:15 PM

270

VIP152 Is a Novel CDK9 Inhibitor with Efficacy in Chronic Lymphocytic Leukemia

Steven Sher^1,2^*, Larry Beaver, BS³^*, Katie Williams, MS³^*, Shelley Orwick, B.S.³^*, Brandi R. Walker, BS³^*, Charles Thomas Gregory, BS³^*, Matthew Purcell, BS³^*, Alexander Pan, BS⁴^*, Pearlly S. Yan, PhD⁴^*, Amy J. Johnson, PhD⁵, Melanie M. Frigault, PhD⁵, Joy M. Greer⁵^*, Ahmed Hamdy, MD⁵, Raquel Izumi, PhD⁵, Stuart Hwang, PhD⁵^*, James S. Blachly, MD³, John C. Byrd, MD^5,6 and Rosa Lapalombella, PhD³

¹Division of Hematology, Department of Internal Medicine, THE OHIO STATE UNIVERSITY, COLUMBUS, OH
²Medical Scientist Training Program, The Ohio State University, Columbus, OH
³Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
⁴The Ohio State University, Columbus, OH
⁵Vincerx Pharma Inc, Palo Alto, CA
⁶Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

802.O1.6 802. Chemical Biology and Experimental Therapeutics